Laverock Therapeutics
Laverock Therapeutics, established in 2021 to commercialise a gene editing induced gene silencing (GEiGS) platform for all human therapeutic applications
Laverock Therapeutics has raised €26M across 3 funding rounds from 9 investors, most recently a Grant round in Jun 2026. Based in Stevenage, UK; active in Healthtech. Data as of 28 Oct 2026.
Stevenage, UKwww.laverocktx.com ↗
Total raised
€26M
€25,725,320
Funding rounds
3
Investors
9
distinct backers
Active since
2023-10
latest 2026-06
Funding by year
EUR raised per year · 2026 YTDLaverock Therapeutics — funding by year — interactive chart.
Data table
| Laverock Therapeutics — funding by year | |
|---|---|
| 2023 | €16M |
| 2025 | €7.6M |
| 2026 | €2.5M |
Signals
Medium confidenceRaise-next likelihood39
base rate 45% for Grant
- ▲ In typical raise window
- ▼ Down/flat last round
Exit likelihood18
base rate 11% (2+ rounds)
- ▲ Recent equity round, but funding momentum is down (may be rescue financing)
Timing: in window vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-06-01 | Grant | €2.5M | — | View deal → |
| 2025-06-30 | Seed | €7.6M | Calculus Capital,Eli lilly and company,Eos Advisory,Maven Capital Partners,Mercia Ventures,Norcliffe Capital | View deal → |
| 2023-10-02 | Seed | €16M | Calculus Capital,Eli lilly and company,EOS Ventures,Maven Capital Partners,Mercia Ventures,Tekfen Ventures+1 more | View deal → |